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Approximately 10% of metastatic tumors eventually reach
the heart or pericardium, and almost every type of malignant
tumor has been known to do so. Secondary neoplasms are 20
to 40 times more common than primary cardiac malignan-
cies. In an effort to define better the broad spectrum of the
metastatic tumors reaching the heart and their diverse clini-
cal behavior, we present this rare case of a symptomatic, iso-
lated urothelial carcinoma of the bladder metastatic to the
heart.
CLINICAL SUMMARY
A 66-year-old man was referred to our department for
a large pericardial effusion and cardiac tamponade. He
also had a nonproductive cough and a worsening progres-
sive dyspnea of several days’ duration. His medical history
included a radical cystectomy and urinary diversion (ileal
conduit after Bricker procedure) performed 5 years previ-
ously for a high-grade infiltrating urothelial carcinoma
(World Health Organization classification) of the urinary
bladder (T2N0M0), with negative results of follow-up since
then.
The echocardiogram revealed a multilobular mass at-
tached to the wall of the right atrium with no blood flow
in it, extending beyond the tricuspid valve annulus and com-
promising its function. A subxiphoid pericardiocentesis
drained approximately 2000 mL of bloody fluid, the cyto-
logic examination of which showed many mesothelial cells
and other cells with uncertain morphologic features. After
the patient’s condition was stabilized, he underwent chest
computed tomography and magnetic resonance imaging,
which revealed an enhancing cardiac mass involving the
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to the right ventricle and into the origin of the pulmonary ar-
tery (Figure 2A). A full-body workup followed, including
bone scan and computed tomographic scans of the head,
chest, abdomen, and pelvis, all of which yielded negative re-
sults for other metastatic sites.
Transvenous endomyocardial biopsy of this mass was
performed. Histologic examination of the specimen showed
infiltration of the myocardium by an undifferentiated neo-
plasm formed by epithelioid cells with eosinophilic cyto-
plasm and eccentric atypical nuclei with signet ring–like
morphology (Figure 1A). Histochemically, the cells stained
positively with periodic acid–Schiff and negatively with Al-
cian blue. Immunohistochemically, they expressed cytoker-
atin 7, cytokeratin AE1, epithelial membrane antigen, the
anti-adhesion molecules mucins 1 and 2, vimentin, and
p63 (Figure E1). They did not express uroplakin, CD56, syn-
aptophysin, chromogranin, the myogenic differentiation
transcription factor 1, desmin, smooth muscle actin, CD34,
CD117, thyroid transcription factor 1, thrombomodulin, or
calretinin. The reevaluation of the histologic slides from
the patient’s cystectomy specimen showed the same
neoplasm infiltrating the urinary bladder (Figure 1B); the
neoplasm in the myocardium was therefore considered to
be metastatic urothelial (transitional cell) carcinoma.
After this diagnosis the patient followed a chemotherapy
regimen based on carboplatin and gemcitabine, with a 40%
reduction of the size of the cardiac mass and a reduction of
the pericardial effusion seen on 6-month follow-up chest
magnetic resonance imaging (Figure 2B). A year after the
original diagnosis, the patient is free of symptoms and has
no sign of disease spread outside the heart. The size of the
metastatic tumor has remained stable.
DISCUSSION
Bladder cancer is the fourth most common cancer among
men and the tenth most common among women. Localized
bladder cancer is classified as superficial disease, limited to
the mucosa and lamina propria, or invasive disease, extend-
ing into the muscularis and beyond. Locoregional control
with radical cystectomy offers the best opportunity for sur-
vival; administration of adjuvant chemotherapy to patients
with organ-confined bladder cancer (stage T1 or T2) does
not provide either a survival advantage or an improvementardiovascular Surgery c Volume 136, Number 5 1377
Brief CommunicationsFIGURE 1. A, Photomicrograph of urothelial carcinoma metastatic to myocardium. B, Urothelial carcinoma infiltrating urinary bladder muscular wall (primary
tumor). (Hematoxylin–eosin stain, original magnification 403).FIGURE 2. Coronal magnetic resonance images demonstrating metastatic tumor involving entire right side of heart and infiltrating myocardium before (A)
and after (B) chemotherapy resulting in 40% reduction in size.in local control after cystectomy. Dissemination of urothelial
carcinoma of the bladder generally follows predictable pat-
terns, first involving regional and juxtaregional lymph
nodes, then spreading to the liver, lungs, and bones and,
less commonly, involving the intestine, adrenal glands and
kidneys.1
This case presents uncommon features. Isolated metasta-
sis of bladder tumors to the heart is extremely rare, with only
2 other reported cases.2 Such a long survival—more than
a year after diagnosis of the metastatic disease—has never
been reported in any similar case to our knowledge, with sur-
vival among patients with cardiac metastases known to be
uniformly poor. Finally, clinical manifestations were pres-
ent, although cardiac metastases are usually clinically silent
and rarely produce symptoms, the most common being peri-
cardial effusion or cardiac tamponade.3,4
Because of the advanced stage at diagnosis, curative sur-
gery is only possible for a minority of patients with cardiac
metastatic tumors, especially when this is the only site of dis-1378 The Journal of Thoracic and Cardiovascular Sease and the primary tumor is under control or when metas-
tases result in right ventricular outflow tract obstruction.4,5
In this setting, surgical debulking may ameliorate symptoms
and prolong survival, as may chemotherapy, which our pa-
tient elected. Otherwise, surgical therapy is usually limited
to relief of recurrent pericardial effusions or tamponade, usu-
ally through subxiphoid pericardiotomy.
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